TP53 and lung adenocarcinoma: Although EGFR, ALK, and ROS1 are common driver mutations in lung adenocarcinoma with effective targeted therapies approved for use30,31, we found no correlations between their mutational status, KRAS or TP53 mutational status, or other clinicopathological variables and the establishment of primary cultures.